How long is a typical CJC-1295 cycle?
Preclinical CJC-1295 No DAC research protocols typically run 8-12 weeks of daily pre-sleep administration, often paired with ipamorelin for dual-receptor GH-axis engagement. The protocol length is set by the integrated IGF-1 axis response time course rather than by the short plasma half-life of CJC-1295 itself.
What the research literature says
The CJC-1295 No DAC protocol-length framework is informed by both the broader CJC-1295 development program (anchored to the DAC variant) and the No-DAC-variant-specific research literature. The Jetté identification work (PMID 15817669) and the Teichman clinical-pharmacology study (PMID 16352683) established the GHRH-receptor pharmacology that anchors protocol design. The Sackmann-Sala serum-protein-profile work documented downstream IGF-1 axis biomarker responses across sustained GH/IGF-1 axis activation (PMID 19386527).
The 8-12 week protocol length aligns with the IGF-1 axis response time course — circulating IGF-1 elevation in response to daily GHRH-receptor stimulation requires 1-2 weeks to reach steady-state, and longer protocols are needed to characterise the integrated tissue-level downstream effects. The Alba GHRH-knockout mouse model framework supports the multi-week protocol design (PMID 16822960).
The combined CJC-1295 + Ipamorelin protocol framework uses similar 8-12 week protocol lengths because the dual-receptor pharmacology produces additive GH-axis effects without altering the underlying IGF-1 axis response time course.
Why this matters in research context
The 8-12 week protocol length is the operational anchor for most CJC-1295 No DAC research protocols. The daily pre-sleep dosing cadence supports the pulsatile GH-release pharmacology characterised in the Ionescu pulsatile-secretion work (PMID 17018654). Cycle on/off practice — alternating multi-week on-periods with shorter off-periods — is more common with GH-axis compounds than with tissue-repair compounds, often using 8-week on / 4-week off patterns across longer research programs.
Related compounds
- CJC-1295 No DAC 10mg — the compound covered by this answer
- CJC-1295 + Ipamorelin Blend — combined-formulation
Related research questions
References
- Jetté L et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005;146(7):3052-3058. [PMID 15817669]
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006;91(3):799-805. [PMID 16352683]
- Alba M et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab 2006;291(6):E1290-E1294. [PMID 16822960]
- Sackmann-Sala L et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res 2009;19(6):471-477. [PMID 19386527]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. CJC-1295 No DAC is sold strictly as a research-grade reagent for laboratory and bench research applications.